Investment Thesis
Bio Essence Corp exhibits severe financial distress with negative stockholders' equity of -$3.1M and deteriorating operational performance including 41.3% YoY revenue decline. The company faces imminent solvency risk with current ratio of 0.06x, indicating critical liquidity constraints and inability to meet near-term obligations. While positive operating cash flow provides temporary relief, the underlying business fundamentals are deeply challenged with negative operating margins of -31.0% and minimal cash reserves.
Strengths
- Strong gross margin of 68.2% suggests viable product pricing
- Positive operating cash flow of $328.7K demonstrates some cash generation capability
- Free cash flow of $325.1K with 77.8% FCF margin shows non-cash charges may be inflating losses
Risks
- Negative stockholders' equity of -$3.1M indicates balance sheet insolvency and technical bankruptcy
- Severe liquidity crisis with current ratio of 0.06x and only $28.7K cash against $3.3M liabilities
- Revenue collapse of 41.3% YoY combined with negative operating margin of -31.0% signals business model failure
- Total liabilities of $3.3M exceed total assets of $184.5K by 17.9x, creating existential refinancing risk
- No insider support with zero Form 4 filings in last 90 days suggests management lack of confidence
Key Metrics to Watch
- Quarterly revenue trend and path to profitability
- Stockholders' equity trajectory and capital restructuring plans
- Operating cash flow sustainability and working capital management
- Debt refinancing status and covenant compliance
Financial Metrics
Revenue
418.1K
Net Income
-132.9K
EPS (Diluted)
$0.00
Free Cash Flow
325.1K
Total Assets
184.5K
Cash
28.7K
Profitability Ratios
Gross Margin
68.2%
Operating Margin
-31.0%
Net Margin
-31.8%
ROE
N/A
ROA
-72.0%
FCF Margin
77.8%
Balance Sheet & Liquidity
Current Ratio
0.06x
Quick Ratio
0.01x
Debt/Equity
N/A
Debt/Assets
1,781.0%
Interest Coverage
-239.14x
Long-term Debt
57.8K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-21T02:20:16.031712 |
Data as of: 2025-09-30 |
Powered by Claude AI